Americans can now legally buy cheaper drugs from Canada—if FDA approves the pharmacies.

What it does

This bill allows Americans to legally import prescription drugs from licensed Canadian pharmacies for personal use, up to a 90-day supply at a time, provided the drugs are FDA-approved in the U.S., prescribed by a U.S. doctor, and purchased from a pharmacy certified by the FDA. The bill excludes controlled substances, biologics, injectables, and complex biotech drugs. The FDA has 180 days to write the rules.

Why we flagged it

The bill's operative mechanism is to expand consumer choice and access to lower-cost medications by legalizing a specific import pathway. It is fundamentally a price-competition and affordability measure, not a deregulation or safety rollback—it adds FDA oversight of Canadian pharmacies rather than removing it.

What the text implies

• Pharmaceutical manufacturers may face downward price pressure in the U.S. market if significant volume shifts to lower-cost Canadian imports, potentially affecting R&D investment incentives.
• The bill's 180-day regulatory timeline may be tight for FDA to establish robust certification and monitoring infrastructure for Canadian pharmacies, creating implementation risk.
• Exclusion of biologics and complex biotech drugs (monoclonal antibodies, recombinant DNA products) limits the bill's scope to small-molecule drugs, leaving high-cost specialty medications outside the program.
• The 90-day supply limit and personal-use-only restriction may not fully address affordability for chronic conditions requiring larger quantities or for patients seeking to stockpile during price spikes.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary Americans gain access to lower-cost prescription drugs through a legal, regulated channel, reducing out-of-pocket medication expenses. The bill includes safety guardrails (FDA certification of pharmacies, physician prescription requirement, exclusion of high-risk drug classes) to protect consumers while expanding choice.

Who stands to gain

• Consumers / patients (lower out-of-pocket drug costs)
• Canadian pharmacies (increased volume from U.S. customers)

Named in the bill

FDA (Food and Drug Administration), Canadian pharmacies, U.S. pharmaceutical manufacturers, Controlled Substances Act, Public Health Service Act, Federal Food, Drug, and Cosmetic Act

Where it stands

7 cosponsors: 5 Democrats, 1 Independents, 1 Republicans.

• Feb 19, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 19, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.